Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Summary

• TARA’s leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil).
• Their recent Phase 2 ADVANCED-2 trial also showed favorable results in NMIBC, with a notable 72% complete response rate at six months.
• TARA’s pipeline also has IV Choline, which could target unmet needs in patients requiring parenteral nutrition, and it has no other FDA-approved alternatives.
• I also believe their cash reserves and recent raise secure their runway, at least until 2027.
• So, even though TARA remains a relatively speculative microcap, I believe it trades at a compelling valuation in light of its potential. So I rate it a “Buy” at these levels.

sefa ozel

Protara Therapeutics, Inc. (NASDAQ:TARA) is basically a clinical-stage biopharmaceutical company with oncological and rare disease programs. Currently, their leading candidate is TARA-002, which is an inactivated strain of Streptococcus pyogenes with immune-stimulating properties. This particular treatment comes from the same

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.